Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 7,864 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Type 2 Diabetes
Interventions: automated telephone intervention vs. usual care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Memory Disorders, Mild Cognitive Impairment, Dementia, Social Isolation, Caregiver Burden
Interventions: Social Reminder System; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Interventions: Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 66 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more

Conditions: Diabetes
Interventions: Medtronic MiniMed 530G Insulin Pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 43
States / cities: Little Rock, Arkansas • Escondido, California • Fresno, California + 38 more

Conditions: Solid Tumors
Interventions: BI 1831169, anti-PD-1 antibody; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more

Conditions: Patient Satisfaction
Interventions: Not listed
Lead sponsor: Dental Practice-Based Research Network; Network
Eligibility: 13 Years and older
Enrollment: 5,932 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more

Conditions: Alopecia
Interventions: iGrow Hair Growth System, Capillus352, HairMax Ultima 12 Lasercomb, HairMax Laserband 82; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 85 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: Endovascular Aneurysm Repair; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Fusion, Radiculopathy Lumbar, Chronic Pain
Interventions: DRG Neurostimulation with Spinal Fusion; Device
Lead sponsor: SynerFuse, Inc; Other
Eligibility: 21 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Mishawaka, Indiana • Minneapolis, Minnesota

Conditions: Healthy
Interventions: Foods with beta-glucan from oats and barley; Other
Lead sponsor: General Mills; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Herpes Labialis
Interventions: iontophoretic acyclovir; Device
Lead sponsor: Transport Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Transanal Endoscopic Surgery
Interventions: Perianal access device; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia
Interventions: cyclophosphamide, fludarabine phosphate; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 215
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 140 more

Conditions: Neoplasms, Head and Neck
Interventions: GSK1363089 (foretinib); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Macular Degeneration
Interventions: TAC-PF, Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more

Conditions: Severe Tricuspid Regurgitation
Interventions: Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System, Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 9 more

Conditions: Hay Fever, Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal spray; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more

Conditions: Stress Disorders, Post-Traumatic, Combat Disorders, Ptsd, Nightmare, Nightmares, REM-Sleep Type, Nightmare Disorder With Associated Non-Sleep Disorder
Interventions: NightWare Therapeutic System, Sham NightWare; Device
Lead sponsor: NightWare; Industry
Eligibility: 22 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Bethesda, Maryland • Minneapolis, Minnesota • Cleveland, Ohio + 1 more

Conditions: Cystic Fibrosis
Interventions: tgAAVCF; Genetic
Lead sponsor: Targeted Genetics Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: Contraception
Interventions: MR-100A-01; Drug
Lead sponsor: Mylan Technologies Inc.; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 96
States / cities: Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more

Conditions: Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: management of therapy complications; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 73
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Search by objective public record fields.

Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes

A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

DPBRN Patient Satisfaction With Dental Restorations

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

Endovascular Aneurysm Repair (EVAR) Gate Study

SynerFuse Spinal Fusion and Neuromodulation Proof of Concept Study

Beta-glucan, Product Claims and Satiety

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Perianal Operating Scope Feasibliity

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NightWare Randomized Trial 02

Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis